Roche presented new data for OCREVUS and fenebrutinib at ECTRIMS 2025. OCREVUS subcutaneous injection maintained a consistent benefit-risk profile over two years, similar to its intravenous form. New data showed OCREVUS significantly reduces disability progression risk in adults with advanced PPMS. One-year data from MINORE and SOPRANINO studies indicated most infants exposed to OCREVUS during pregnancy or breastfeeding developed protective antibody responses to vaccines. OCREVUS also demonstrated significant benefit in preventing disability progression in children with RRMS. Two-year Phase II data for fenebrutinib demonstrated near-complete suppression of disease activity in relapsing MS patients. Fenebrutinib patients showed zero new active MRI lesions and maintained normal neurofilament light chain levels. Roche is encouraged by fenebrutinib's potential to redefine future MS treatment. The company presented a total of 25 abstracts at the congress. Roche continues its commitment to advancing MS treatment through innovative research.